News | November 10, 2025
Venus Remedies expands ASEAN presence with new drug approvals in Vietnam
Venus Remedies now has 29 active product approvals in Vietnam alone
Venus Remedies now has 29 active product approvals in Vietnam alone
Relmada expects to initiate its Phase 3 program in the first half of 2026
SMS Pharmaceuticals has reported total income of Rs. 243.86 crore during the period ended September 30, 2025
Bayer remains a key partner in Ginkgo Bioworks’ growing agricultural biologicals platform
Glenmark will begin distribution in November 2025
Dr Agarwals Health Care has reported total income of Rs. 506.62 crore during the period ended September 30, 2025
Dr Agarwals Eye Hospital has reported total income of Rs. 118.40 crore during the period ended September 30, 2025
Vitiligo, affecting over 90 per cent of patients in its non-segmental form, is characterized by symmetrical white patches on both sides of the body
Advancing toward Phase 2a evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track designation
Glenmark’s Ropivacaine Hydrochloride Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug Naropin Injection of Fresenius Kabi USA
Subscribe To Our Newsletter & Stay Updated
